MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Reconciliation of Non-GAAP Adjusted Income (Adjusted EBITDA)” Post this “Our broad-based growth in the third quarter reflects […]
Other News
Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months
WASHINGTON–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study evaluating the safety and performance of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) for the treatment of moderate to severely calcified coronary artery lesions demonstrating safety […]
RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position
RapidAI’s leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 30, 2024 /PRNewswire/ — Recently Frost & Sullivan researched the…
Enlitic, Inc. Joins ‘Radiology Reimagined’ Demonstration at RSNA 2024
Enlitic joins ‘Radiology Reimagined’ at RSNA 2024, showcasing AI integration in radiology workflow with data standardization tech demo.
Hello Heart Appoints Bill Otten as Commercial President
MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the digital leader in preventive heart health, today announced the appointment of healthcare industry veteran Bill Otten as Commercial President, reporting into Maayan Cohen, CEO and co-founder. He joins the company following another recent key hire, renowned cardiologist Jayne Morgan, MD who joined as VP, Medical Affairs. Together […]
MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System
MADRID–(BUSINESS WIRE)–MedLumics, a medical device company developing fiber optically guided platform technologies for the treatment, initially, of Atrial fibrillation (AF), announced today 10 patients treated in the company’s First in Man clinical trial. The AblaView Unipolar Pulsed Field (PF) Ablation System, used in this trial, features MedLumics unique, real-time, fiber […]
egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading cardiovascular digital health company, today announced the results of its seminal research on the real-world impact of clinical presentation among patients with moderate or greater aortic stenosis (AS) undergoing aortic valve replacement (AVR). Presented by Philippe Généreux, MD, Director of the Structural Heart […]
Cardiawave Announces Positive Six-Month Data from Valvosoft Pivotal Study at Transcatheter Cardiovascular Therapeutics (TCT) Conference
WASHINGTON–(BUSINESS WIRE)–Cardiawave SA, developer of the groundbreaking Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis (CAS), today announced that the device met the primary endpoint in its pivotal study and improved or stabilized heart failure symptoms for 80.5% of patients, substantially improving hemodynamics […]
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE PATCH Pivotal Study evaluating the safety and efficacy of the Vivasure PerQseal® Closure Device System, at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 annual conference in Washington, D.C. […]
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy (EXAMINE-HCM) study have been published […]



